cIAP2 represses IKKα/β-mediated activation of MDM2 to prevent p53 degradation

Cell Cycle

Volumn 11, Issue 21, 2012, Pages 4009-4019

  Lau, Rosanna ^a   Niu, Min Ying ^a   Pratt, M A Christine ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Cellular inhibitors of apoptosis (cIAPs); I B kinases (IKKs); Murine double minute 2 (MDM2); p53; Phosphorylation SUMOylation

Indexed keywords

I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; INHIBITOR OF APOPTOSIS PROTEIN 2; MESSENGER RNA; NUTLIN 3; PROTEIN MDM2; PROTEIN P53; SMALL INTERFERING RNA;

ARTICLE; BREAST CELL; COLONY FORMATION; DOWN REGULATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; SUMOYLATION;

EID: 84869462358     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.22223     Document Type: Article

References (66)

1. Eckelman BP, Salvesen GS, Scott FL. Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep 2006; 7:988-94; PMID:17016456; http://dx.doi.org/10.1038/sj.embor.7400795.
2. Choi YE, Butterworth M, Malladi S, Duckett CS, Cohen GM, Bratton SB. The E3 ubiquitin ligase cIAP1 binds and ubiquitinates caspase-3 and -7 via unique mechanisms at distinct steps in their processing. J Biol Chem 2009; 284:12772-82; PMID:19258326; http://dx.doi.org/10.1074/jbc.M807550200.
3. Mahoney DJ, Cheung HH, Mrad RL, Plenchette S, Simard C, Enwere E, et al. Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB activation. Proc Natl Acad Sci USA 2008; 105:11778-83; PMID:18697935; http://dx.doi.org/10.1073/pnas. 0711122105.
4. Bertrand MJ, Milutinovic S, Dickson KM, Ho WC, Boudreault A, Durkin J, et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 2008; 30:689-700; PMID:18570872; http://dx.doi.org/10.1016/j. molcel.2008.05.014.
5. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P, et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 2007; 131:669-81; PMID:18022362; http://dx.doi.org/10.1016/j.cell.2007.10.030.
6. Zarnegar BJ, Wang Y, Mahoney DJ, Dempsey PW, Cheung HH, He J, et al. Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat Immunol 2008; 9:1371-8; PMID:18997794; http://dx.doi.org/10.1038/ni.1676.
7. Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU, et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 2007; 131:682-93; PMID:18022363; http://dx.doi.org/10.1016/j.cell.2007.10.037.
8. Wright CW, Duckett CS. Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function. J Clin Invest 2005; 115:2673-8; PMID:16200201; http://dx.doi.org/10.1172/JCI26251.
9. Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 2006; 125:1253-67; PMID:16814713; http://dx.doi.org/10.1016/j.cell.2006.05.030.
10. Xu L, Zhu J, Hu X, Zhu H, Kim HT, LaBaer J, et al. c-IAP1 cooperates with Myc by acting as a ubiquitin ligase for Mad1. Mol Cell 2007; 28:914-22; PMID:18082613; http://dx.doi.org/10.1016/j.molcel.2007.10.027.
11. Schimmer AD. Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res 2004; 64:7183-90; PMID:15492230; http://dx.doi.org/10.1158/0008-5472.CAN-04-1918.
12. LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, Korneluk RG. IAP-targeted therapies for cancer. Oncogene 2008; 27:6252-75; PMID:18931692; http://dx.doi.org/10.1038/onc.2008.302.
13. Fulda S. Targeting inhibitor of apoptosis proteins (IAPs) for cancer therapy. Anticancer Agents Med Chem 2008; 8:533-9; PMID:18537535.
14. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006; 441:431-6; PMID:16724054; http://dx.doi.org/10.1038/nature04870.
15. Bassères DS, Baldwin AS. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 2006; 25:6817-30; PMID:17072330; http://dx.doi.org/10.1038/ sj.onc.1209942.
16. Häcker H, Karin M. Regulation and function of IKK and IKK-related kinases. Sci STKE 2006; 2006:re13; PMID:17047224; http://dx.doi.org/10.1126/ stke.3572006re13.
17. Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004; 25:280-8; PMID:15145317; http://dx.doi.org/10.1016/j.it.2004.03.008.
18. Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA 2001; 98:11598-603; PMID:11504915; http://dx.doi.org/10.1073/pnas.181181198.
19. Zhou BP, Liao Y, Xia W, Zou Y, Spohn B, Hung MC. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 2001; 3:973-82; PMID:11715018; http://dx.doi.org/10.1038/ncb1101-973.
20. Ogawara Y, Kishishita S, Obata T, Isazawa Y, Suzuki T, Tanaka K, et al. Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J Biol Chem 2002; 277:21843-50; PMID:11923280; http://dx.doi.org/10.1074/jbc.M109745200.
21. Grossman SR, Deato ME, Brignone C, Chan HM, Kung AL, Tagami H, et al. Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science 2003; 300:342-4; PMID:12690203; http://dx.doi.org/10.1126/science.1080386.
22. Miyauchi Y, Yogosawa S, Honda R, Nishida T, Yasuda H. Sumoylation of Mdm2 by protein inhibitor of activated STAT (PIAS) and RanBP2 enzymes. J Biol Chem 2002; 277:50131-6; PMID:12393906; http://dx.doi.org/10.1074/jbc.M208319200.
23. Lee MH, Lee SW, Lee EJ, Choi SJ, Chung SS, Lee JI, et al. SUMO-specific protease SUSP4 positively regulates p53 by promoting Mdm2 self-ubiquitination. Nat Cell Biol 2006; 8:1424-31; PMID:17086174; http://dx.doi.org/10.1038/ncb1512.
24. Tergaonkar V, Pando M, Vafa O, Wahl G, Verma I. p53 stabilization is decreased upon NFkappaB activation: a role for NFkappaB in acquisition of resistance to chemotherapy. Cancer Cell 2002; 1:493-503; PMID:12124178; http://dx.doi.org/10.1016/S1535-6108(02)00068-5.
25. Xia Y, Padre RC, De Mendoza TH, Bottero V, Tergaonkar VB, Verma IM. Phosphorylation of p53 by IkappaB kinase 2 promotes its degradation by beta-TrCP. Proc Natl Acad Sci USA 2009; 106:2629-34; PMID:19196987; http://dx.doi.org/10.1073/ pnas.0812256106.
26. Dawson PJ, Wolman SR, Tait L, Heppner GH, Miller FR. MCF10AT: a model for the evolution of cancer from proliferative breast disease. Am J Pathol 1996; 148:313-9; PMID:8546221.
27. Conze DB, Albert L, Ferrick DA, Goeddel DV, Yeh WC, Mak T, et al. Posttranscriptional down-regulation of c-IAP2 by the ubiquitin protein ligase c-IAP1 in vivo. Mol Cell Biol 2005; 25:3348-56; PMID:15798218; http://dx.doi.org/10.1128/MCB.25.8.3348-3356.2005.
28. Meek DW, Anderson CW. Posttranslational modification of p53: cooperative integrators of function. Cold Spring Harb Perspect Biol 2009; 1:a000950; PMID:20457558; http://dx.doi.org/10.1101/cshper-spect.a000950.
29. Dai C, Gu W. p53 post-translational modification: deregulated in tumorigenesis. Trends Mol Med 2010; 16:528-36; PMID:20932800; http://dx.doi.org/10.1016/j.molmed.2010.09.002.
30. Lu J, Bai L, Sun H, Nikolovska-Coleska Z, McEachern D, Qiu S, et al. SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. Cancer Res 2008; 68:9384-93; PMID:19010913; http://dx.doi.org/10.1158/0008-5472.CAN-08- 2655.
31. Varfolomeev E, Alicke B, Elliott JM, Zobel K, West K, Wong H, et al. X chromosome-linked inhibitor of apoptosis regulates cell death induction by proapoptotic receptor agonists. J Biol Chem 2009; 284:34553-60; PMID:19854829; http://dx.doi.org/10.1074/jbc. M109.040139.
32. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303:844-8; PMID:14704432; http://dx.doi.org/10.1126/science. 1092472.
33. de Toledo SM, Azzam EI, Dahlberg WK, Gooding TB, Little JB. ATM complexes with HDM2 and promotes its rapid phosphorylation in a p53-independent manner in normal and tumor human cells exposed to ionizing radiation. Oncogene 2000; 19:6185-93; PMID:11175332; http://dx.doi.org/10.1038/ sj.onc.1204020.
34. Ringshausen I, O'Shea CC, Finch AJ, Swigart LB, Evan GI. Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell 2006; 10:501-14; PMID:17157790; http://dx.doi.org/10.1016/j.ccr. 2006.10.010.
35. Xirodimas DP, Chisholm J, Desterro JM, Lane DP, Hay RT. P14ARF promotes accumulation of SUMO-1 conjugated (H)Mdm2. FEBS Lett 2002; 528:207-11; PMID:12297306; http://dx.doi.org/10.1016/S0014-5793(02)03310-0.
36. Meek DW, Knippschild U. Posttranslational modification of MDM2. Mol Cancer Res 2003; 1:1017-26; PMID:14707285.
37. Schmidt D, Müller S. Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity. Proc Natl Acad Sci USA 2002; 99:2872-7; PMID:11867732; http://dx.doi.org/10.1073/ pnas.052559499.
38. Liu B, Yang Y, Chernishof V, Loo RR, Jang H, Tahk S, et al. Proinflammatory stimuli induce IKKalpha-mediated phosphorylation of PIAS1 to restrict inflammation and immunity. Cell 2007; 129:903-14; PMID:17540171; http://dx.doi.org/10.1016/j. cell.2007.03.056.
39. Ferbeyre G, de Stanchina E, Lin AW, Querido E, McCurrach ME, Hannon GJ, et al. Oncogenic ras and p53 cooperate to induce cellular senescence. Mol Cell Biol 2002; 22:3497-508; PMID:11971980; http://dx.doi.org/10.1128/MCB.22.10.3497- 3508.2002.
40. Liu Z, Li H, Derouet M, Filmus J, LaCasse EC, Korneluk RG, et al. ras Oncogene triggers up-regulation of cIAP2 and XIAP in intestinal epithelial cells: epidermal growth factor receptor-dependent and -independent mechanisms of ras-induced transformation. J Biol Chem 2005; 280:37383-92; PMID:16115895; http://dx.doi.org/10.1074/jbc.M503724200.
41. Ma O, Cai W-W, Zender L, Dayaram T, Shen J, Herron AJ, et al. MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression. Cancer Res 2009; 69:2559-67; PMID:19276372; http://dx.doi.org/10.1158/0008-5472.CAN-08-2929.
42. Zerbini LF, Wang Y, Czibere A, Correa RG, Cho JY, Ijiri K, et al. NF-kappa B-mediated repression of growth arrest- and DNA-damage-inducible proteins 45alpha and gamma is essential for cancer cell survival. Proc Natl Acad Sci USA 2004; 101:13618-23; PMID:15353598; http://dx.doi.org/10.1073/ pnas.0402069101.
43. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007; 12:131-44; PMID:17692805; http://dx.doi.org/10.1016/ j.ccr.2007.07.003.
44. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007; 12:115-30; PMID:17692804; http://dx.doi.org/10.1016/j.ccr.2007.07.004.
45. Rossi D, Deaglio S, Dominguez-Sola D, Rasi S, Vaisitti T, Agostinelli C, et al. Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma. Blood 2011; 118:4930-4; PMID:21881048; http://dx.doi.org/10.1182/blood-2011-06-359166.
46. Liao G, Zhang M, Harhaj EW, Sun SC. Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J Biol Chem 2004; 279:26243-50; PMID:15084608; http://dx.doi.org/ 10.1074/jbc.M403286200.
47. Vallabhapurapu S, Matsuzawa A, Zhang W, Tseng PH, Keats JJ, Wang H, et al. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat Immunol 2008; 9:1364-70; PMID:18997792; http://dx.doi.org/10. 1038/ni.1678.
48. He JQ, Zarnegar B, Oganesyan G, Saha SK, Yamazaki S, Doyle SE, et al. Rescue of TRAF3-null mice by p100 NF-kappa B deficiency. J Exp Med 2006; 203:2413-8; PMID:17015635; http://dx.doi.org/10.1084/jem.20061166.
49. Grech AP, Amesbury M, Chan T, Gardam S, Basten A, Brink R. TRAF2 differentially regulates the canonical and noncanonical pathways of NF-kappaB activation in mature B cells. Immunity 2004; 21:629-42; PMID:15539150; http://dx.doi.org/10.1016/j.immuni.2004.09.011.
50. Demchenko YN, Glebov OK, Zingone A, Keats JJ, Bergsagel PL, Kuehl WM. Classical and/or alternative NF-kappaB pathway activation in multiple myeloma. Blood 2010; 115:3541-52; PMID:20053756; http://dx.doi.org/10.1182/blood-2009-09- 243535.
51. O'Mahony A, Lin X, Geleziunas R, Greene WC. Activation of the heterodimeric IkappaB kinase alpha (IKKalpha)-IKKbeta complex is directional: IKKalpha regulates IKKbeta under both basal and stimulated conditions. Mol Cell Biol 2000; 20:1170-8; PMID:10648602; http://dx.doi.org/10.1128/MCB.20.4.1170- 1178.2000.
52. Meek DW, Hupp TR. The regulation of MDM2 by multisite phosphorylation - opportunities for molecular-based intervention to target tumours? Semin Cancer Biol 2010; 20:19-28; PMID:19897041; http://dx.doi.org/10.1016/j.semcancer.2009. 10.005.
53. Li J, Peet GW, Balzarano D, Li X, Massa P, Barton RW, et al. Novel NEMO/IkappaB kinase and NF-kappa B target genes at the pre-B to immature B cell transition. J Biol Chem 2001; 276:18579-90; PMID:11279141; http://dx.doi.org/10. 1074/jbc.M100846200.
54. Perkins ND. The diverse and complex roles of NF-κB subunits in cancer. Nat Rev Cancer 2012; 12:121-32; PMID:22257950.
55. Schumm K, Rocha S, Caamano J, Perkins ND. Regulation of p53 tumour suppressor target gene expression by the p52 NF-kappaB subunit. EMBO J 2006; 25:4820-32; PMID:16990795; http://dx.doi.org/10.1038/sj.emboj.7601343.
56. O'Prey J, Crighton D, Martin AG, Vousden KH, Fearnhead HO, Ryan KM. p53-mediated induction of Noxa and p53AIP1 requires NFkappaB. Cell Cycle 2010; 9:947-52; PMID:20160496; http://dx.doi.org/10.4161/cc.9.5.10872.
57. Oren M, Cooks TNF. NFκB and p53: A life and death affair. Cell Cycle 2010; 9:1027; PMID:20237416; http://dx.doi.org/10.4161/cc.9.6.11099.
58. Azmi AS, Banerjee S, Ali S, Wang Z, Bao B, Beck FW, et al. Network modeling of MDM2 inhibitor-oxaliplatin combination reveals biological synergy in wt-p53 solid tumors. Oncotarget 2011; 2:378-92; PMID:21623005.
59. Hanson JL, Hawke NA, Kashatus D, Baldwin AS. The nuclear factor kappaB subunits RelA/p65 and c-Rel potentiate but are not required for Ras-induced cellular transformation. Cancer Res 2004; 64:7248-55; PMID:15492243; http://dx.doi.org/10.1158/0008-5472.CAN-03-3898.
60. Batsi C, Markopoulou S, Vartholomatos G, Georgiou I, Kanavaros P, Gorgoulis VG, et al. Chronic NF-kappaB activation delays RasV12-induced premature senescence of human fibroblasts by suppressing the DNA damage checkpoint response. Mech Ageing Dev 2009; 130:409-19; PMID:19406145; http://dx.doi.org/10.1016/j.mad.2009.04.002.
61. Miliani de Marval PL, Zhang Y. The RP-Mdm2-p53 pathway and tumorigenesis. Oncotarget 2011; 2:234-8; PMID:21406728.
62. Pan W, Issaq S, Zhang Y. The in vivo role of the RP-Mdm2-p53 pathway in signaling oncogenic stress induced by pRb inactivation and Ras overexpression. PLoS One 2011; 6:e21625; http://dx.doi.org/10.1371/journal.pone.0021625; PMID:21747916.
63. Rossi D, Fangazio M, Rasi S, Vaisitti T, Monti S, Cresta S, et al. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood 2012; 119:2854-62; PMID:22308293; http://dx.doi.org/10.1182/blood-2011-12-395673.
64. Sanlioglu S, Williams CM, Samavati L, Butler NS, Wang G, McCray PB Jr., et al. Lipopolysaccharide induces Rac1-dependent reactive oxygen species formation and coordinates tumor necrosis factor-α secretion through IKK regulation of NF-κ B. J Biol Chem 2001; 276:30188-98; PMID:11402028; http://dx.doi.org/10.1074/jbc.M102061200.
65. Pratt MA, Bishop TE, White D, Yasvinski G, Ménard M, Niu MY, et al. Estrogen withdrawal-induced NF-kappaB activity and bcl-3 expression in breast cancer cells: roles in growth and hormone independence. Mol Cell Biol 2003; 23:6887-900; PMID:12972607; http://dx.doi.org/10.1128/MCB.23.19.6887-6900. 2003.
66. Liston P, Roy N, Tamai K, Lefebvre C, Baird S, Cherton-Horvat G, et al. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. Nature 1996; 379:349-53; PMID:8552191; http://dx.doi.org/10.1038/ 379349a0.